1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porters Fiver Forces Analysis 39
3 Segmentation of Asia Pacific Market by Product Type 43
3.1 Market Overview by Product Type 43
3.2 Recombinant Non-glycosylated Biosimilars 45
3.2.1 Insulin 47
3.2.2 Recombinant Human Growth Hormone (rHGH) 48
3.2.3 Granulocyte Colony Stimulating Factor 49
3.2.4 Interferon 50
3.3 Recombinant Glycosylated Biosimilars 51
3.3.1 Monoclonal Antibodies (mAb) 52
3.3.2 Erythropoietin (EPO) 53
3.3.3 Follicle Stimulating Hormone 54
3.4 Recombinant Peptides and Others 55
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 56
3.4.2 Parathyroid Hormone 57
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 58
4 Segmentation of Asia Pacific Market by Indication 59
4.1 Market Overview by Indication 59
4.2 Cancer 61
4.3 Autoimmune Disease 62
4.4 Blood Disorder 63
4.5 Diabetes 64
4.6 Growth Hormone Deficiency 65
4.7 Infectious Diseases 66
4.8 Other Indications 67
5 Segmentation of Asia Pacific Market by Manufacturing 68
5.1 Market Overview by Manufacturing 68
5.2 Contract Manufacturing 70
5.3 Inhouse Manufacturing 71
6 Segmentation of Asia Pacific Market by End User 72
6.1 Market Overview by End User 72
6.2 Hospitals and Clinics 74
6.3 Research Institutes 75
6.4 Other End Users 76
7 Asia-Pacific Market 2019-2030 by Country 77
7.1 Overview of Asia-Pacific Market 77
7.2 Japan 80
7.3 China 83
7.4 Australia 85
7.5 India 87
7.6 South Korea 89
7.7 Rest of APAC Region 91
8 Competitive Landscape 93
8.1 Overview of Key Vendors 93
8.2 New Product Launch, Partnership, Investment, and M&A 97
8.3 Company Profiles 98
AMEGA Biotech S.A. 98
Apotex Inc. 100
Biocon Ltd 101
Biogen Inc. 102
Boehringer Ingelheim 103
Celltrion, Inc. 104
Dr. Reddys Laboratories Ltd. 105
Eli Lilly and Company 106
Intas Pharmaceuticals Ltd. 107
LG Chem, Ltd. 108
Merck and Co. Inc. 109
Mylan N.V. 110
Pfizer Inc. 111
Samsung Biologics Co., Ltd. 112
Sandoz International GmbH 113
STADA Arzneimittel AG 114
Teva Pharmaceutical Industries Ltd. 115
RELATED REPORTS 116